Haemonetics has entered into a non-exclusive supply agreement with CSL Plasma for its NexSys PCS devices and Persona PLUS technology. This agreement is driving a significant stock price increase, despite the company not adjusting its financial guidance yet, indicating strong market optimism.
Haemonetics (HAE) announced a non-exclusive supply agreement with CSL Plasma Inc., allowing CSL to adopt Haemonetics’ NexSys PCS devices and Persona PLUS technology across its U.S. network. This is a significant commercial win for Haemonetics, as evidenced by the stock hitting a new 52-week high and a price target increase from BTIG. While the company has not yet updated its financial guidance, the market is reacting positively to the potential for increased sales of devices and disposables. The short-term implication is a strong bullish sentiment for HAE, driven by anticipated future revenue growth. The long-term opportunity lies in the potential for broader adoption of Haemonetics' technology within the plasma collection industry, though the non-exclusive nature and lack of minimum purchase commitments introduce some risk regarding the ultimate scale of implementation.